NRAS and melanoma: When two or more SNVs were detected at different time points, the ctDNA dynamics of these variants showed an overlapping or parallel trend consistent with clinical response (Fig. 4 and Table 3), regardless of whether they were melanoma drivers (BRAF p.V600E/K, NRAS p.Q61L, RAC1 p.P29S, PTEN p.L247*) or variants of uncertain significance (ADAMTS18 p.G115E, ATM p.L2490F, E1F1AX p.G8R, and KIT p.S147F)36.